GSK Statement on First Phase 1 Trial Results of a Candidate Ebola Vaccine

November 24, 2014 First results from a small phase 1 trial published today in the New England Journal of Medicine show that a GSK/NIH Ebola candidate vaccine was well-tolerated and produced an immunological response in each of the 20 healthy adult volunteers in the USA who received it. The candidate vaccine used in the trial conducted by the National Institutes …

ebola vaccine bigpharma

Is the WHO Blaming BigPharma for Ebola?

No. They’re blaming governments for not investing. WHO Director General, Dr. Margaret Chan, said on Monday that the lack of an Ebola vaccine is due to Ebola historically being confined to poor ‘African nations. At the regional committee for Africa in Benin on Monday, Dr. Chan, Director general of the World Health Organization, said that  ‘Ebola emerged nearly four decades …

Amongst the flurry of efforts to combat the West African Ebola outbreak, Johnson & Johnson is trying its hand at developing a vaccine

Johnson & Johnson To Fast Track Ebola Vaccine Trials

Amongst the flurry of efforts to combat the West African Ebola outbreak, Johnson & Johnson is trying its hand at developing a vaccine Johnson & Johnson can be counted amongst the ranks of yet another pharmaceutical company that has joined the race to develop an Ebola vaccine. Thus far, the most advanced vaccine candidate is Glaxo Smith Kline’s, which is the …

Ebola Vaccine Using Immunovaccine’s DepoVax Proves Highly Efficacious in Non-Human Primate Study

Ebola Vaccine Using Immunovaccine’s DepoVax Proves Highly Efficacious in Non-Human Primate Study August 25th, 2014 Immunovaccine Inc. (“Immunovaccine”) (TSX-V: IMV), a clinical stage vaccine company, today announced positive results for a vaccine formulated in its DepoVax™ technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). …